The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients

Not Applicable

Completed

• Conditions: HIV Infections; Candidiasis, Oral

• Registration Number: NCT00002431
• Lead Sponsor: Procter and Gamble

Brief Summary

To evaluate the safety and effectiveness of Peridex (an oral rinse containing chlorhexidine gluconate) for preventing the occurrence of clinically-evident microbiologically-documented oral candidiasis in HIV-positive patients, who are at risk of the disease based on previous history of candidiasis.

Detailed Description

Not available

Study Timeline

• Status Verified: 1993-11
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (5)

Bering Dental Clinic; 🇺🇸 Houston, Texas, United States

Hermann Hosp / Univ Texas Health Science Ctr; 🇺🇸 Houston, Texas, United States

UCSF / Stomatology Clinical Ctr; 🇺🇸 San Francisco, California, United States

Dental Research Institute / UCLA Med Ctr; 🇺🇸 Los Angeles, California, United States

Ohio State Univ Hosp Clinic; 🇺🇸 Columbus, Ohio, United States